Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Sandeep M. Nayak, Matthew W. Johnson
Tasman’s Psychiatry 2023 DOI: 10.1007/978-3-030-42825-9_94-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA Addiction |
| Keywords | Psychedelic Hallucinogen Disorders Harm Risks Psychosis |
| Key findings | Classic psychedelics and MDMA are associated with a range of adverse effects including acute toxicity, abuse potential, persistent perceptual effects, psychosis, and neurotoxicity. |
Abstract
Hallucinogens are a broad category of substances encompassing drugs with diverse pharmacological, phenomenological, and adverse effects. In this chapter, the focus is on disorders caused by and exacerbated by two classes of hallucinogens. These are classic psychedelics (drugs including LSD and psilocybin that exert subjective effects principally by 5HT_2A agonism) and the substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA). In this chapter, the evidence regarding disorders and other adverse effects attributable to these drugs, including acute toxicity, abuse potential, persistent perceptual effects (Hallucinogen Persisting Perception Disorder), psychosis, neurotoxicity, and more, are explored.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cites 121
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 116 more in the library